Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Recursion Pharmaceuticals
Recursion Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?